As Congress considers lowering drug costs, pharma CEOs target key senators with campaign cash
WASHINGTON — Top pharmaceutical CEOs have targeted a small group of Republican senators with roughly $200,000 in campaign donations in the past year, according to a STAT review of campaign finance disclosures.
The focus on Congress comes as drug executives are holding back on donations to presidential candidates. No major industry executive has contributed to a Democratic presidential contender or President Trump’s reelection campaign, according to the review. Only one — David Ricks, the CEO of the Indiana-based drugmaker Eli Lilly — has given to a committee associated with Vice President Mike Pence, who once served as Indiana’s governor.
